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Skeletal malformationceptor-like 1 (FGFRL1) is a recently discovered transmembrane protein whose
functions remain unclear. Since mutations in the related receptors FGFR1-3 cause skeletal malformations,
DNA samples from 55 patients suffering from congenital skeletal malformations and 109 controls were
searched for mutations in FGFRL1. One patient was identiﬁed harboring a frameshift mutation in the
intracellular domain of this novel receptor. The patient showed craniosynostosis, radio-ulnar synostosis and
genital abnormalities and had previously been diagnosed with Antley–Bixler syndrome. The effect of the
FGFRL1 mutation was studied in vitro. In a reporter gene assay, the wild-type as well as the mutant receptor
inhibited FGF signaling. However, the mutant protein differed from the wild-type protein in its subcellular
localization. Mutant FGFRL1 was mainly found at the plasma membrane where it interacted with FGF ligands,
while the wild-type protein was preferentially located in vesicular structures and the Golgi complex. Two
motifs from the intracellular domain of FGFRL1 appeared to be responsible for this differential distribution, a
tandem tyrosine based motif and a histidine-rich sequence. Deletion of either one led to the preferential
redistribution of FGFRL1 to the plasma membrane. It is therefore likely that mutant FGFRL1 contributes to the
skeletal malformations of the patient.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionOrganogenesis and pattern formation are controlled by many
cytokines and growth factors, including the ﬁbroblast growth factors
(FGFs). In human beings and mice, the FGFs form a large family of 22
structurally related proteins that bind with varying afﬁnity to four
different FGF receptors (FGFR1–FGFR4) [1–3]. Binding to the receptors
is stabilized by heparin and heparan sulfate chains. The FGFRs belong
to the tyrosine kinase receptors and contain three extracellular
immunoglobulin (Ig)-like domains, a single transmembrane domain
and an intracellular tyrosine kinase domain. Upon binding of ligands
and heparin, the receptors dimerize and transduce the signal to the
interior of the cells by autophosphorylation of selected tyrosine
residues at the cytoplasmic domain [4].
A while ago, we discovered an additional FGFR in a cartilage-
speciﬁc cDNA library and termed it FGFRL1 [5]. Independently, two
other research groups described the same receptor and termed it
FGFR5 [6,7]. Similar to the classical FGFRs, FGFRL1 contains three
extracellular Ig-like domains and a single transmembrane domain.
However, in contrast to the classical receptors, it lacks the intracellular
tyrosine kinase domain, but instead contains a short cytoplasmic tail
of ∼100 amino acid residues with a peculiar histidine-rich motif.rch, Murtenstr. 35, PO Box 43,
ll rights reserved.Conserved sequences for FGFRL1 are found in vertebrates from ﬁsh to
man [8–10] and in the cephalochordate amphioxus [11], but not in the
urochordate Ciona or in other invertebrates. In vitro, recombinant
FGFRL1 interacts with FGF2 andwith heparin [9]. However, in contrast
to the classical FGFRs, it forms constitutive dimers at the surface of the
cells even in the absence of FGF or heparin. These dimers promote cell
adhesion in a way similar to other adhesion molecules located at cell-
cell junctions [12].
FGFRL1 is expressed primarily in cartilage and some muscles [13].
Our current data suggest that FGFRL1 has a negative effect on cell
growth and a positive effect on cell differentiation. When over-
expressed in osteosarcoma cells, it inhibits cell proliferation [9]. In
ovary tumors, its synthesis is largely perturbed when compared to
matched control tissues [14]. In a zebraﬁsh model, inhibition of
FGFRL1 synthesis with the help of morpholino constructs inhibited
the proper development of the pharyngeal arches, suggesting a role
for FGFRL1 in cartilage formation [15]. Recently, we have prepared a
mouse model with a targeted disruption of the Fgfrl1 gene [16]. These
knock-out mice develop normally until birth, but die immediately
after birth due to respiratory failure. The respiratory problems are
explained by a reduction of the diaphragmmuscle, which is not strong
enough to inﬂate the lungs after birth. Thus, FGFRL1 plays a critical
role in the development of cartilage and the diaphragm.
Germline mutations in FGFRs cause a variety of skeletal disorders
[17,18]. Craniosynostosis, a relatively common malformation of the
human skull, occurs in approximately one of 2500 individuals [18].
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primarily in FGFR2 and FGFR1. Missense mutations, deletions,
insertions and splice mutations have been identiﬁed causing a variety
of syndromes such as Pfeiffer, Crouzon, Jackson-Weiss, Apert, Beare-
Stevenson and Antley–Bixler. Mutations in FGFR3 mostly lead to
malformations of the limbs as observed in chondrodysplasias, but can
also cause Muenke syndrome and Crouzon syndrome with acanthosis
nigricans.
In this report, we analyzed the FGFRL1 gene from 55 patients with
different congenital skeletal disorders. We found one patient with
a craniosynostosis syndrome who had a frameshift mutation in the
C-terminal domain of the FGFRL1 sequence. Our in vitro studies
indicate that themutated FGFRL1 protein differs signiﬁcantly from the
wild-type protein in its subcellular localization.
2. Materials and methods
2.1. Genomic sequencing
Various genomic DNA samples were purchased from the European
Collection of Cell Cultures (ECACC, Salisbury, England): human
random control DNA panel HRC-1, human craniosynostosis panel
HC-1, and Antley–Bixler BV0954, BV0956, NP0003. Genomic DNAwas
also isolated from blood leukocytes of several patients followed at the
University Children's Hospital of Bern. For these samples ethical
approval and informed consent was obtained. DNAwas extractedwith
the QIAamp DNA Blood Kit according to the supplier's recommenda-
tions (Qiagen, Hilden, Germany). All protein coding exons of the
FGFRL1 gene were ampliﬁed from the genomic DNA by PCR using
speciﬁc primer pairs and the GC-rich PCR System from Roche
Diagnostics (Rotkreuz, Switzerland). Primer sequences and ampliﬁca-
tion conditions were as follows: exon 1, ACCCTTTGTCTGCCTTTGATAC-
CCAC/GGGCACTGTGGCAGGGTTCAG, annealing temperature 66 °C,
product length 360 bp; exon 2, CAGTGCTCAGGGCTTTGGTGCATGTG/
GCAGGGCACCGAAGGAAGGCTTTC, 66 °C, product 613 bp; exon 3,
CCCCTCACCTGCCCTCCCTGTG/CCTCCGGCCGCAGGTTCTTCAG, 66 °C,
product 427 bp; exon 4, CCTTGGCTGCATCCCCGTCCTC/ACTCTACCC-
CGCCAGCACCCTG, 66 °C, 0.5 M resolution solution, product 402 bp;
exon 5, CAAGGTGGATGTGATCCGTGAGTGTG/GACCAGGAGAGCA-
CCCCAGACCCATC, 66 °C, 0.5 M resolution solution, product 772 bp;
exon 6, TACAGCTTCCGCAGCGCCTTCCTCAC/CTGCCTTCGTCTGCAG-
CTCCGTCCTC, 72 °C, product 806 bp. For the subcloning of exon 6,
two nested primers with restriction sites were used (CGGGATCCAGC-
ATGGGTCTCCGGCAG/CGAATTCGTGCCCAC TGCAGATAC, 60 °C) and the
product of 210 bp was cloned into the Bam HI/Eco RI sites of pUC19. In
addition, another primer pair was used for independent veriﬁcation
and subcloning of the patient's mutation, CTCCTGTGGCTTTGCCAGG/
CACGTGCTCCCTGAAGGCACACGT (64 °C, product 566 bp). The primer
sequences and conditions for the analysis of the P450 oxidoreductase
gene have been described previously [19]. Exon 8 of this gene was
ampliﬁed with the primer pair GCAACCAGAAGCGTCCTTGGAGAC/
GCCACGTGGTCCCCAGATTCATAC at 64 °C (product 321 bp). Subcloning
into the Xba I/Eco RI sites of pUC19 was performed with the primer
pair GCATCTAGAAGCGTCCTTGGAG/CCGAATTCATACCTGGAGGGAG
(63 °C, product 309 bp). The sequences of the PCR fragments and of
the pUC inserts were determined by cycle sequencing followed by
capillary electrophoresis (Microsynth, Balgach, Switzerland). All
sequences were analyzed and aligned with the GCG computer
program from Accelrys Software Inc. (Cambridge, UK).
2.2. Cell cultures
All cell lines were obtained from the American Type Culture
Collection: human osteosarcoma cells MG63 (CRL-1427), human
chondrosarcoma cells SW1353 (HTB 94), human rhabdomyosar-
coma cells A204 (HTB-82), human embryonic kidney cells HEK293(CRL-1573), human lung ﬁbroblasts VA13 (CCL 75.1), Chinese hamster
ovary cells CHO-K1 (CCL-61), mouse embryonic ﬁbroblasts 3T3
(CCL-163), and mouse osteoblast-like cells MC3T3-E1 (CRL-2593).
Most of these cells were maintained at 37 °C under an atmosphere of
5% v/v CO2 in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplementedwith 10% v/v fetal bovine serum,100 units/ml penicillin
and 100 µg/ml streptomycin. The medium for SW1353 cells, CHO-K1
cells and HEK293 cells under puromycin selection was further
enriched with non-essential amino acids. MC3T3-E1 cells were
propagated in α-minimum essential medium (αMEM).
2.3. Plasmids
The reading frame for human FGFRL1 [5] was inserted into the Bam
HI/Xba I site of the expression vector pcDNA3.1 (Invitrogen, Carlsbad
CA). For most studies, a special version of pcDNA3 was used, in which
the neomycin resistance gene had been replaced by the puromycin
resistance gene. Several truncated versionswere derived from the full-
length construct by PCR. These covered the nucleotide sequences for
amino acids 1-416 (FGFRL1ΔC), 1-468 (FGFRL1ΔTyrΔHis), and 1-478
(FGFRL1ΔHis). Likewise, the open reading frame for FGFRL1 from
patient BV0449 was inserted into the Bam HI/ RI site of pcDNA3.1. The
dominant negative version of human FGFR1 was ampliﬁed by PCR
from IMAGE clone 3911101 and ligated into the Bam HI/Xho I site of
pcDNA3.1. The ﬁnal construct covered amino acid residues 1-415
(FGFR1ΔC), but lacked the intracellular tyrosine kinase domain. The
ExSite PCR-based technique was used for site-directed mutagenesis
(Stratagene Europe, Amsterdam NL). PCR was performed with a
forward primer that harbored the desired mutation and a phosphory-
lated reverse primer that annealed immediately adjacent to the 5′ end
of the forward primer. After ampliﬁcation of the entire plasmid, the
maternal DNAwas digested with Dpn I, and the ends of the remaining
product were joined by T4 DNA ligase. The open reading frames of all
constructs were veriﬁed by DNA sequencing.
2.4. Transient and stable transfections
Cells were grown on cover slips in 30 mm plastic dishes.
Subconﬂuent cultures were transfected with selected plasmids utili-
zing Metafectene according to the instructions of the manufacturer
(Biontex, Martinsried, Germany). 5 h after transfection, the medium
was replaced with regular medium and the transfected cells were
used for speciﬁc experiments 15 h later.
For stable transfections, cells were grown in 75 cm2 cell culture
ﬂasks. At 70% optical conﬂuence, the cells were transfected with
selected plasmids utilizingMetafectene as described above. After 24 h,
the transfected cultures were split into two culture ﬂasks and
supplemented with 1 µg/ml puromycin (Invivogen, San Diego CA).
On the following day, puromycin was increased to 2 µg/ml and then
kept at this concentration until resistant colonies became visible
(4 weeks). All individual colonies from one transfection were pooled
to yield an oligoclonal puromycin resistant cell population.
2.5. Reporter gene assay
The FGF inducible responsive element FiRE [20] was ampliﬁed by
PCR from genomic mouse DNA (NT039548.6 position 5787210–
5787500) and cloned into the Sac I/Nhe I sites of the luciferase
reporter vector pGL3 (Promega Catalys, Switzerland). The authenticity
of the FiRE element was veriﬁed by DNA sequencing. Subconﬂuent
MC3T3-E1 cells were co-transfected with this FiRE-luciferase reporter
vector (0.3 µg per 30 mm dish) and the wild-type or mutant FGFRL1
expression plasmids (1 µg per 30 mm dish) as described above. After
5 h, the transfection mediumwas replaced by medium supplemented
with only 0.3% v/v fetal bovine serum. 1 day later, the cells were
stimulated with FGF2 (15 ng/ml) and heparin (150 ng/ml). On the
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(PBS), lysed and processed for measurement of luciferase activity
using the Luciferase Assay System (Promega E45530).
The expression plasmids used for transfection harbored the
cDNA sequences for human FGFRL1 (AJ277437) or for human FGFR1
lacking the tyrosine kinase domain (FGFR1ΔC, see above) cloned into
pcDNA3.1 (Invitrogen, Carlsbad CA). For RNAi-mediated down-
regulation of the endogenous Fgfrl1mRNA, synthetic oligonucleotides
(Microsynth, Balgach, Switzerland) were ligated into the Bgl II/Hind III
sites of the H1-RNA promoter vector pSuper (OligoEngine, Seattle,
WA). These oligonucleotides were designed according to the pSuper
protocol of the supplier and included the nucleotides GAAGAAGTG-
GACACTGAGC (sense, position 685–703) and GCTCAGTGTCCACTTCTTC
(antisense, position 703–685) of the mouse Fgfrl1 cDNA (AJ293947).
2.6. Northern blots
Total RNA was isolated from stably transfected cell lines by the
guanidinium isothiocyanate method utilizing the RNeasy kit from
Qiagen GmbH (Hilden, Germany). The RNA was separated on a 1%
agarose gel and processed for Northern blotting as previously
described [9].
2.7. Antibodies
Monoclonal antibodies against human FGFRL1 were selected from
a recombinant phage display library (HuCAL Gold). To this end, the
extracellular domain of human FGFRL1 was expressed in HEK293 cells
[12] and screened against 1.5×1010 Fab fragments utilizing an auto-
mated panning process (Morphosys, Antibodies by Design, Martins-
ried, Germany). Selected antibodies were expressed in bacteria and
puriﬁed by afﬁnity chromatography. Polyclonal antibodies against
human TGN46 and monoclonal antibodies against human LAMP1
(G1/137) were a kind gift from Dr. M. Spiess, University of Basel,
Switzerland. Secondary antibodies were obtained from Jackson
Immunoresearch Laboratories (West Grove, PA), namely goat anti-
mouse IgG (Cy3 conjugated) and goat anti human IgG F(ab)2 (Cy2 and
Cy3 conjugated). All the antibodies were diluted to the recommended
working concentrations in PBS containing 1 mg/ml bovine serum
albumin, except for anti-LAMP1 that was diluted in PBS containing
1 mg/ml bovine serum albumin plus 0.5% w/v saponin.
2.8. Immunoﬂuorescence
Cells on coverslips were ﬁxed for 10 min in 4% w/v paraformalde-
hyde in PBS. After two washing steps with PBS, the cells were
permeabilized for 10 minwith 0.2% v/v Triton X-100 in PBS and rinsed
twice with PBS. After blocking for 30 min with 1% w/v bovine serum
albumin in PBS, the cells were incubated for 1 h with the primary
antibody (1 µg/ml in the case of monoclonal antibodies against
FGFRL1). Following three washing steps with 0.1% v/v Tween 20 in
PBS, the cells were incubated for 1 h with the secondary antibody.
After washing as above, the cells were counterstained with 4′,6′-
diamino-2-phenylindole dihydrochloride (DAPI). Alternatively, they
were incubated for 15 min at 37 °C with 100 µg/ml RNase A, rinsed
twice with PBS and counterstained with acridine orange. Finally, the
coverslips were mounted with Mowiol and inspected with a Nikon
Eclipse E1000 M microscope (Nikon Corp. Tokyo, Japan) or with a
confocal LSM510 instrument equipped with an Axiovert 100 M
microscope (Carl Zeiss, Germany).
2.9. Ligand binding assay
FGF2 (Invitrogen) was labeled with DyLight 547-NHS ester (Pierce,
Rockford IL) according to the manufacturer's instructions and
stabilized with 2 mg/ml bovine serum albumin. Living cells that hadbeen transfected transiently or stably with different FGFRL1 con-
structs were chilled to 4 °C and incubated for 1 hwith the labeled FGF2
preparation (1 µg/ml) and heparin (7.5 µg/ml). The cells were then
thoroughly rinsed with cold PBS and ﬁxed with 4% w/v paraformal-
dehyde (see above). After a permeabilization step with 0.2% v/v
Triton X-100, the cells were counterstained with monoclonal anti-
bodies against FGFRL1 (see above) and inspected by epiﬂuorescence
microscopy.
3. Results
3.1. Identiﬁcation of the ﬁrst mutation in the FGFRL1 gene
Genomic DNA from 55 patients suffering from a broad spectrum of
congenital skeletal malformations (including 22 patients with non-
syndromic craniosynostosis and 19 with short stature) as well as DNA
from 109 Caucasian controls was analyzed for polymorphisms and
mutations in the FGFRL1 gene. All protein coding exons were
ampliﬁed with primers that annealed outside of the coding regions
and the PCR fragments were subjected to direct DNA sequencing.
Several polymorphisms were identiﬁed in the DNA of the patients as
well as the controls. In addition, one patient was found with a
frameshift mutation in exon 6 shortly before the end of the open
reading frame. Downstream of the dinucleotide repeat (AC)n encoding
the histidine-rich tail, this patient had an insertion of the four
nucleotides ACAC. Since the mutation occurred only on one allele, the
sequence of the genomic DNA was superimposed starting at the
insertion (Fig. 1A). After subcloning of the PCR product into the vector
pUC19, the two alleles were isolated in a 1:1 ratio, each displaying a
clean sequence, one without and the other with the 4 nucleotide
insertion. The mutation caused an elongation of the encoded
polypeptide by 47 residues before a stop codon was reached at
amino acid position 551 (Fig. 1B). The insertionwas not simply caused
by a PCR artefact since it could be veriﬁed with a different primer pair.
Furthermore, none of the 109 controls showed a similar insertion at
this locus.
The genomic DNA originated from a female patient who had been
diagnosed with the Antley–Bixler craniosynostosis syndrome (OMIM
207410) [21]. The patient suffered from craniosynostosis and radio-
ulnar synostosis and showed genital malformations including clito-
romegaly and labial fusion. Since Antley–Bixler syndromewith genital
anomalies may also be caused by P450 oxidoreductase mutations
[19,22,23] and since a heterozygous P450 oxidoreductase mutation
has already been described in this patient, we re-screened the
genomic DNA for mutations in this gene. We found two mutations,
the common A287P mutation in exon 8 that changed alanine 207 into
proline, and a novel mutation at the 3′ splice junction of exon 8
changing the donor sequence AGgtacca into AGatacca (Fig. 1C). In
silico analysis revealed that translation of the corresponding poly-
peptide would proceed to the next stop codon 45 nucleotides (15
amino acids) downstream of the mutated site if this splice site were
neglected by the splicing machinery. Subcloning of the PCR product
from exon 8 further showed that each mutation occurred on a
separate allele (Fig. 1C). Thus, the patient harbored both a hetero-
zygous FGFRL1 mutation and two heterozygous P450 oxidoreductase
mutations. Unfortunately, no DNA was available from the parents of
this patient for a detailed genetic analysis, especially with regard to
the origin of the FGFRL1 mutation.
3.2. Effect of FGFRL1 on FGF signaling
To gain mechanistic insight into the action of FGFRL1, a cell based
reporter gene assay was performed. Transactivation activity of wild-
type and mutant FGFRL1 was assessed when co-transfected with the
FiRE luciferase reporter into osteoblastic cells. FiRE is a 170 bp FGF
inducible responsive element derived from the syndecan-1 gene that
Fig. 1.Mutations in FGFRL1 and P450 oxidoreductase in a craniosynostosis patient. (A) Partial sequence of exon 6 from FGFRL1 demonstrating heterozygosity for the 4 nucleotide insertion ACAC. After subcloning, the insertion is found only on
one allele. (B) Alignment of the C-terminal amino acid sequences derived from the mutated allele of the patient and from a normal control. (C) Compound heterozygosity of the same patient for the P450 oxidoreductase mutation A287P (left
side) and the splice mutation (right side). After subcloning, the A287P mutation is found on one allele, the splice mutation on the other. The nucleotide and derived amino acid sequences are given below the chromatograms.
115
T.Rieckm
ann
et
al./
Biochim
ica
et
Biophysica
A
cta
1792
(2009)
112
–121
Fig. 2. Effects of FGFRL1 on FGF signaling. A plasmid containing the luciferase reporter gene under the control of the FiRE enhancer was co-transfected with the expression vectors
pcDNA3.1 (A) or pSuper (B) into MC3T3-E1 cells. One half of the culture dishes was stimulated with FGF2 (15 ng/ml), while the other half was left untreated. After 24 h, the cells were
lysed and luciferase activity was determined. Stimulation of the cells with FGF2 led to a 10-fold induction of luciferase activity (A). This induction was partially reduced by FGFRL1
transcribed from wild-type DNA, from the DNA of the craniosynostosis patient or from the DNA of a dominant negative FGFR1 variant that lacked the intracellular kinase domain
(FGFR1ΔC). On the other hand, the induction was further enhanced by down-regulation of the endogenous mRNA for FGFRL1 via a hairpin RNA transcribed from the pSuper vector
(B). All bars give the mean of three independent experiments +/− SD. The values were normalized to controls performed with empty vector (100% corresponded to an actual number
of 555,849 cpm in (A) and to 183,231 cpm in (B)). Previous Northern blotting experiments with stably transfected C2C12 myoblasts or MC3T3 osteoblasts had indicated that the
pSuper construct efﬁciently down-regulated the endogenous FGFRL1 mRNA (C). The lane on the right of the blot shows cells transfected with the RNAi pSuper construct, the lane on
the left shows cells transfected with the empty pSuper vector. The blot was hybridized with a radioactively labeled probe for FGFRL1. As a loading control, the 28S ribosomal RNA
stained with ethidium bromide is included.
116 T. Rieckmann et al. / Biochimica et Biophysica Acta 1792 (2009) 112–121is speciﬁcally activated by FGFs in mesenchymal cells [20]. Stimulation
of FiRE transfected cells with 15 ng/ml FGF2 showed a ten-fold
induction of luciferase activity (Fig. 2A). This inductionwas reduced to
one third when the wild-type, full-length construct of FGFRL1 was co-Fig. 3. Subcellular localization of FGFRL1. SW1353 chondrosarcoma cells were transfected
truncated form FGFRL1ΔC (residues 1–416) or the frameshift mutation of the craniosynosto
antibodies, followed by Cy3 conjugated secondary antibodies (red). The trans-Golgi network
secondary antibodies (green). Scale bar=10 µm. Wild-type FGFRL1 is found in the trans-Go
preferentially located at the plasma membrane.transfected into the cells together with the reporter gene, suggesting
that FGFRL1 exerts a negative effect on FGF signaling. A slightly
stronger reduction was observed when the deletion construct
FGFR1ΔC lacking the intracellular tyrosine kinase domain was co-with expression constructs corresponding to the wild-type sequence of FGFRL1, the
sis patient. After ﬁxation and permeabilization, FGFRL1 was detected with monoclonal
protein TGN46 was visualized with polyclonal antibodies, followed by Cy2 conjugated
lgi network and in vesicle-like structures. The truncated and the mutated proteins are
117T. Rieckmann et al. / Biochimica et Biophysica Acta 1792 (2009) 112–121transfected together with the reporter gene. This FGFR1 variant has
previously been demonstrated to exert a dominant negative effect on
FGF signaling [24]. When the mutated FGFRL1 construct harboring the
4 nucleotide insertion from the reported craniosynostosis patient was
utilized in the reporter assay, a signiﬁcant reduction of FGF signaling
was observed as well.
It is conceivable that down-regulation of endogenous FGFRL1
mRNA will have a positive effect on FGF signaling when over-
expression of FGFRL1 has a negative effect. RNA interference was
utilized to investigate this possibility (Fig. 2B). Small interfering RNAs
for the FGFRL1 mRNA were introduced into the osteoblastic cells by
transfection of a pSuper construct that contained 19 nucleotides of the
FGFRL1 cDNA. As expected, the presence of these interfering
oligonucleotides led to a nearly two-fold increase in FiRE luciferase
activity in comparison to control cells transfected with the empty
pSuper vector and stimulated with FGF2 (Fig. 2B).
3.3. Subcellular localization of wild-type and mutant FGFRL1
Since there was barely any difference in the FGF2 mediated
reporter assay between wild-type and mutant FGFRL1, we investi-
gated the subcellular localization of wild-type and mutant proteins in
cultivated SW1353 chondrosarcoma cells. To prepare a reagent that
would be able to detect the untagged protein, we isolated monoclonal
antibodies from a recombinant phage display library. The extracellular
portion of FGFRL1 produced in HEK293 cells served as the speciﬁc
antigen. Eight different antibodies were obtained that reacted with
the non-reduced antigen on dot blots. However, none of the
antibodies reacted with the antigen on a Western blot after reduction
of disulﬁde-bonds with β-mercaptoethanol (not shown). This result
suggests that all antibodies recognize a structural epitope of FGFRL1,
which is stabilized by disulﬁde bonds.Fig. 4.Motifs and signals found in the intracellular domain of FGFRL1. The FGFRL1 sequences
leucine motif, the tyrosine based signal YXXΦ and the histidine-rich sequence are marked.
amino acid positions they encompass and the abbreviations used. TM, transmembrane domThe antibodies were used for visualization of the FGFRL1 pro-
tein in several cultivated cell lines including SW1353, MC3T3-E1, 3T3,
CHO-K1, COS7 and VA13. Surprisingly, none of the antibodies pro-
duced a clear signal with these cells. It is possible that the amount of
endogenous FGFRL1 protein was too low to be detected by our
antibodies. However, a prominent signal was obtainedwhen thewild-
type cDNA sequence for FGFRL1 was transfected into the cells. In this
case, the signal was mainly conﬁned to vesicular structures and the
Golgi complex (Fig. 3). The signal in the Golgi co-localized with the
trans-Golgi network protein TGN46 as demonstrated by double
ﬂuorescence experiments. Unexpectedly, the plasma membrane was
barely stained with our antibodies. This result is in sharp contrast to
our previous ﬁndings obtained with an FGFRL1-GFP fusion construct
[9]. In those experiments, the majority of the ﬂuorescence signal
emitted from the GFP-fusion protein had clearly localized to the
plasmamembrane. It is conceivable that the subcellular distribution of
the GFP-fusion protein differed from that of the wild-type protein due
to some structural differences. Relative to wild-type FGFRL1, the
fusion protein lacked the last amino acid residues (469–504), but
instead contained the GFP moiety at its C-terminus.
To address this hypothesis in detail, we deleted the sequence
corresponding to the intracellular, C-terminal domain from our
untagged wild-type protein. In fact, the resulting construct FGFRL1ΔC
encompassing residues 1–416 revealed a subcellular distribution very
similar to that of the fusion protein FGFRL1-GFP (Fig. 3). An untagged
construct corresponding to the FGFRL1 mutation found in the
craniosynostosis patient revealed basically the same distribution.
Moreover, when a 1:1 mixture of wild-type and mutated constructs
was transfected into theHEK293 cells, immuno-reactive FGFRL1 protein
was found primarily at the cell membrane, too (not shown). Such a
mixture should mimic the situation as it occurs in the craniosynostosis
patient suffering from the heterozygous frame-shift mutation.from six different vertebrates are aligned in (A). Identical residues are boxed. The double
All the different constructs utilized in this study are presented in (B) together with the
ain.
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sequence contains one or several sequence motif(s) that control its
subcellular distribution. These motifs appear to be missing or shieldedin the proteins encoded by FGFRL1ΔC and by the cDNA from the
craniosynostosis patient.
3.4. Motifs in the intracellular C-terminal sequence of FGFRL1
In contrast to the extracellular portion of the FGFRL1 sequence,
the intracellular portion is not well conserved among different
species (Fig. 4A). Nevertheless, a multiple sequence alignment
identiﬁed three conserved motifs that might play a role in protein
trafﬁcking, namely (1) a dileucine sequence occurring 7–9 residues
downstream of two acidic amino acids, (2) two tyrosine motifs
that were arranged in tandem (YXXΦYXXΦ, where Φ is a bulky,
hydrophobic amino acid), and (3) the histidine-rich region that
mainly consists of His-Ser and His-Thr repeats. Dileucine and tyrosine
based motifs are well known mediators of endocytosis and
transmembrane protein trafﬁcking [25], but no similar function has
yet been described for histidine-rich motifs. To study the inﬂuence of
the three motifs on the subcellular distribution of FGFRL1, we
prepared deletion constructs lacking the histidine-rich region
(FGFRL1ΔHis) or the histidine-rich region plus the tandem tyrosine
motif (FGFRL1ΔHisΔTyr) (Fig. 4B). Furthermore, we disrupted the
putative dileucine (L460S) and tyrosine (Y471A, Y475A) motifs by site
directed mutagenesis. The truncated and the mutated constructs
were transiently overexpressed in chondrosarcoma cells and detected
with our antibodies (Fig. 5, left side). Disruption of the putative
dileucine motif (L460S) did not have any effect on the subcellular
distribution of FGFRL1 (not shown). However, deletion of the
histidine-rich region (ΔHis) or the histidine-rich region plus the
tyrosine motifs (ΔHisΔTyr) induced translocation of FGFRL1 to the
plasma membrane. Site directed mutagenesis of either one of the two
tyrosine residues alone (Y471A, Y475A) did not have any effect (not
shown). However, when both tyrosines were mutated in concert, the
resulting protein was relocalized to the plasma membrane.
The results obtained with transient transfections were conﬁrmed
by stably expressing the same constructs in HEK293 cells (Fig. 5, right
side). Wild-type FGFRL1 and FGFRL1 carrying either one of the single
mutations (L460S, Y471A, or Y475A) were found to be localized almost
exclusively in the trans-Golgi network and in vesicular structures.
Deletion of the histidine-rich region or the histidine-rich region plus
the tyrosine motif led to the translocation of the protein to the plasma
membrane. This was particularly well observed at cell-cell contact
sites. As noted with transient transfections, mutation of the two
tyrosines in concert resulted in a phenotype similar to that of
FGFRL1ΔC. These results demonstrate for the ﬁrst time that the C-
terminus of FGFRL1 carries motifs, which efﬁciently regulate the
subcellular distribution of the FGFRL1 protein.
Finally, the subcellular distribution of the mutant FGFRL1 protein
from the craniosynostosis patient was analyzed (Fig. 5, bottom). In
transiently transfected SW1353 cells as well as in stably transfected
HEK293 cells, the FGFRL1 protein with the frameshift mutation was
found predominantly at the cell membrane. The distribution differed
signiﬁcantly from that of the wild-type protein, but corresponded to
that of the FGFRL1ΔC construct. Thus, the frameshift mutation in the
FGFRL1 gene of the craniosynostosis patient caused a signiﬁcant
redistribution of the FGFRL1 protein, probably due to shielding or
functional loss of an important trafﬁcking motif.Fig. 5.Distribution of FGFRL1 in transfected cells. Various FGFRL1 constructs as depicted
in Fig. 4B were transiently transfected into SW1353 cells or stably transfected into
HEK293 cells. After ﬁxation and permeabilization of the cells, FGFRL1 was visualized
with monoclonal antibodies, followed by Cy3 conjugated secondary antibodies (red).
Nuclei were visualized by DAPI (left) or by acridine orange (right) and are presented in
blue. SW1353 cells were inspected by conventional ﬂuorescence microscopy, HEK293
cells were inspected by confocal microscopy. Wild-type FGFRL1 is primarily found in
the trans-Golgi network and in vesicle-like structures. The truncated and mutated
variants are located preferentially at the plasma membrane. Scale bar=10 µm.
Fig. 6. Distribution of FGFRL1 at the cell surface of HEK293 cells. Cells stably transfected with the wild-type FGFRL1 construct were cooled to 4 °C and treated with monoclonal
antibodies against FGFRL1. After threewashing steps, the cells were ﬁxed and incubatedwith Cy3 conjugated secondary antibodies. (A) shows an image taken by confocal microscopy.
For panel (B), the cell nuclei were stained with acridine orange and are presented in blue. (C) shows a merged image obtained by differential interference contrast. Bar=10 µm. The
signal of FGFRL1 is observed at the cell surface in a spotty fashion.
119T. Rieckmann et al. / Biochimica et Biophysica Acta 1792 (2009) 112–1213.5. Endocytosis of cell surface FGFRL1
The virtual absence of wild-type FGFRL1 from the plasma
membrane may be explained in two ways. Either, FGFRL1 reaches
the plasma membrane but is efﬁciently and rapidly internalized
thereafter. Alternatively, the intracellular trafﬁcking machinery
targets the protein directly to another compartment. To address this
question, living HEK293 cells that stably expressed wild-type FGFRL1
were pre-cooled and incubated at 4 °C with our monoclonal
antibodies (Fig. 6). The cells were ﬁxed and a ﬂuorescently labeled,
secondary antibody was added. To ensure the structural integrity of
the cell membrane, no detergent was added before the ﬁnal washing
steps. By confocal microscopy a spotty signal was observed at the
periphery of the cells. This indicates that a fraction of the vesicles
observed before must represent FGFRL1 complexes located at the cell
surface. As expected, the trans-Golgi network was not stained in this
experiment since the cells had not been permeabilized before addition
of the antibodies.
In the next experiment, the antibodies were applied to the living
cells at 37 °C (Fig. 7). After 3 h, the cells were ﬁxed, permeabilized and
co-stained with an antibody against the lysosomal marker protein
LAMP1. Again, we found a spotty signal of vesicle-like structures.
Some of these vesicles co-localized with LAMP1. Thus, a fraction of the
FGFRL1 protein must reach the plasma mem-brane from where it is
rapidly internalized and transported to the lysosomes.
3.6. Retention of mutant FGFRL1 at the cell surface
The experiments with our monoclonal antibodies suggested that
FGFRL1 from the Antley–Bixler patient stayed for a prolonged time at
the cell surface where it might participate in FGF signaling. In an
attempt to directly validate this observation, we performed anFig. 7. Partial co-distribution of FGFRL1 and the lysosomal marker protein LAMP1. Monoclo
transfected with the wild-type FGFRL1 construct. After 3 h, the cells were ﬁxed, permeabiliz
with polyclonal antibodies followed by Cy2 conjugated secondary antibodies (green). A subf
arrowheads. Images were taken by confocal microscopy. DIC, differential interference contrexperiment with ﬂuorescently labeled FGF ligand (Fig. 8). HEK293
cells were transiently transfected with wild-type and mutant FGFRL1
and chilled to 4 °C. A ﬂuorescently labeled preparation of FGF2 was
added and, after an incubation period of 1 h, the distribution of the
label was examined under the microscope. As expected, cells
expressing wild-type FGFRL1 revealed only background staining
since they possessed barely any FGFRL1 at their cell surface. Never-
theless, these cells did produce FGFRL1, which could be detected with
our monoclonal antibodies in the Golgi complex, the endoplasmic
reticulum and the nuclear membrane. In contrast, cells that had been
transfected with the mutant FGFRL1 corresponding to the Antley–
Bixler sequence bound relatively large amounts of FGF2 as revealed by
the red label at the cell surface. In this case, the distributionwas found
to be very similar to that of a control experiment performed with the
truncated version FGFRL1ΔC. Analogous results were also obtained
with stably transfected HEK293 cells (Fig. 8, lower part). Taken
together, these experiments clearly demonstrate that mutant FGFRL1
is retained at the cell surface for a longer period of time than the wild-
type protein and that the fraction of FGFRL1 at the cell surface is able
to interact with extracellular FGF ligands.
4. Discussion
FGFRL1 (also known as FGFR5) is a novel member of the FGFR
family that lacks the intracellular tyrosine kinase domain, but instead
contains a short C-terminal domain of unknown function [9]. We
report here the ﬁrst human mutation in this receptor. The mutation
was identiﬁed in the C-terminal domain of FGFRL1 from a British
patient that has previously been described by Reardon et al. (patient
ID 14683) [21]. This female patient was diagnosed with Antley–Bixler
syndrome (OMIM 207410) and presented with craniosynostosis,
radio-ulnar synostosis and genital anomalies.nal antibodies against FGFRL1 were added to living HEK293 cells that had been stably
ed and stained with a Cy3 conjugated secondary antibody (red). LAMP1 was co-stained
raction of the FGFRL1-positive vesicles was found to be positive for Lamp1 as shown by
ast. Bar=10 µm.
Fig. 8. Retention of mutant FGFRL1 at the cell surface. HEK293 cells that had been
transiently or stably transfected with different FGFRL1 constructs as indicated were
cooled to 4 °C and incubated with a ﬂuorescently labeled preparation of FGF2. The cells
were ﬁxed, permeabilized and incubated with antibodies against FGFRL1, followed by
Cy2 conjugated secondary antibodies. The distribution of FGF2 (red) and FGFRL1 (green)
was inspected by epiﬂuorescence microscopy. Prominent staining of FGF2 at the cell
surface was observed in cells transfected with the mutant construct corresponding to
the ABS patient's sequence and the FGFRL1ΔC construct, but not in cells transfected
with the wild-type construct.
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prises two genetically different variants of the syndrome, an
autosomal dominant form that segregates with mutations in one of
the FGFR genes and an autosomal recessive form that segregates with
mutations in the gene for P450 oxidoreductase [19,22,23]. Antley–
Bixler patients with mutations in P450 oxidoreductase show steroid
hormone abnormalities due to decreased activities of three enzymes
that depend on electron transfer from P450 oxidoreductase, namely
21-hydroxylase, 17α-hydroxylase and aromatase. As a consequence,
such patients present with hormonal and genital anomalies including
hypoplastic labia majora and clitoromegaly in females. In contrast,
Antley–Bixler patients with mutations in one of the FGFRs have
normal steroid proﬁles and normal genitalia [19,22,23]. Mutations in
FGFRs are also found in other craniosynostosis syndromes such asPfeiffer, Apert, Jackson-Weiss and Crouzon syndromes [17,18]. How-
ever, patients with these syndromes do not suffer from abnormalities
in steroid hormone biosynthesis.
Patient 14683 was found to have an abnormal steroid proﬁle and
ambiguous genitalia but no FGFR2 mutation [21]. The relatively
common P450 oxidoreductase mutation A287P was identiﬁed on one
allele, but no mutation was observed on the second allele (patient 16
in [19]). We have now identiﬁed a novel splice site mutation on the
second allele at exon/intron junction 8. Similar splice site mutations
have been identiﬁed in other Antley–Bixler patients at exon/intron
junctions 6 and 7 [19,22]. Hence, patient 14683 is compound
heterozygous for two P450 oxidoreductase mutations that may
explain the disordered steroid proﬁle and the genital anomalies.
In addition to the abnormal genitalia, patient 14683 suffers from
craniosynostosis, brachycephaly, midface hypoplasia, proptosis, choa-
nal stenosis, radio-ulnar synostosis and femoral bowing [19,21]. These
anomalies are typical hallmarks of Antley–Bixler syndrome, but so far
no convincing explanation has been offered for the pathogenesis of
the bone malformations through P450 oxidoreductase mutations.
Moreover, about one third of all the patients with P450 oxidoreduc-
tase mutations do not show any skeletal malformations at all.
We have now demonstrated that patient 14683 harbors amutation
in the FGFRL1 gene in addition to the P450 oxidoreductase mutations,
offering an explanation for the bone phenotype. FGFRL1 binds FGF2
and other FGF ligands similar to all other FGFRs. Although the exact
function of the novel receptor is not known, there is good evidence
that it modulates FGF signaling. We have previously shown that
overexpression of FGFRL1 in osteosarcoma cells inhibits cell growth
and proliferation [9]. In a reporter gene assay, we demonstrated here
(Fig. 2) that it diminishes the stimulatory effect of FGF2 on
transcription of an FGF inducible gene. Taken together, our results
suggest that FGFRL1 exerts a negative effect on FGF signaling.
FGFRL1 is expressed in cartilaginous and bony tissues and in
some muscles [13]. Unexpectedly, mice with a targeted disruption of
the Fgfrl1 gene exhibit only subtle alterations in their skeleton, yet
they die perinatally due to respiratory failure [16]. The respiratory
problems are explained by a severe reduction of the diaphragm
muscle, which is not strong enough to inﬂate the lungs after birth. A
more pronounced cartilage or bone phenotype would probably
become overt in this mouse model after birth when the skeleton
grows at maximal speed. However, our knock-out mice cannot be
investigated at later stages as all of them die immediately after birth.
Nevertheless, newborn Fgfrl1−/− mice exhibit subtle alterations in the
shape of their head, including a dome-shaped skull with high front
(S. Baertschi and B. Trueb, unpublished observation). Similar
alterations have previously been noticed in mice with targeted
mutations in Fgfr1 (P250R) or Fgfr2 (S250W) which had been
created as animal models for human craniosynostosis [18]. Further-
more, Hall et al. [15] studied the expression of Fgfrl1 in a zebraﬁsh
model. These authors used morpholino constructs to inhibit the
expression of the novel receptor and found that the branchial arches
of Fgfrl1 deﬁcient animals failed to complete chondrogenesis. Thus,
Fgfrl1 is crucial for proper cartilage and bone formation, at least at
some speciﬁc sites.
The frameshift mutation observed in FGFRL1 from patient 14683
leads to a clearly different phenotype in cell culture experiments. As
shown with monoclonal antibodies against FGFRL1 and with Cy3-
labeled FGF2, wild-type FGFRL1 is barely located at the cell
membrane, where it could interact with ligands, but is rather found
in vesicular structures and the Golgi complex. In sharp contrast,
mutant FGFRL1 is primarily located at the cell surfacewhere it actively
participates in FGF binding. The subcellular distribution of FGFRL1
appears to be controlled by two (or more) motifs situated in the
intracellular, C-terminal domain of the protein, a histidine-rich region
with 10 histidines distributed over a stretch of 23 residues and a
tandem tyrosine motif YXXΦ, where X denotes any amino acid and Φ
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one of these motifs results in the preferential localization of the
receptor at the plasma membrane. Our experiments suggest that the
two motifs function as signals for trafﬁcking of FGFRL1 from the
plasma membrane to endosomes and lysosomes. While such a
function has not yet been described for the histidine-rich sequence,
it is well documented for YXXΦ motifs [25]. These motifs occur for
instance in the transferrin receptor, in the trans-Golgi network protein
TGN46 and in the lysosomal associated membrane proteins LAMP1
and LAMP2.
The frameshift mutation observed in patient 14683 deletes part of
the histidine-rich motif and increases the length of the C-terminal
domain of FGFRL1 by 45 amino acids. In cell culture experiments, the
mutated protein exhibits an altered subcellular distribution similar to
that of the truncated FGFRL1 version lacking the tyrosine and histidine
motifs. It is therefore likely that the tyrosine and histidine motifs are
shielded in the mutant FGFRL1 protein such that they become non-
functional. Without functional motifs, endocytosis of FGFRL1 will be
delayed and the proportion at the plasma membrane will increase. A
similar effect has recently been described for two point mutations of
FGFR2 that occur in Apert syndrome [26]. After ligand stimulation, the
wild-type FGFR2 protein underwent rapid endocytosis into lysosomes,
whereas the modiﬁed protein with the S252W or P253R mutation
remained at the cellmembrane for an extended period of time, thereby
leading to an elevation of intracellular signaling.
The mutant sequence of the ABS patient has several features in
common with the Fgfrl1 sequences from rat and mouse. During
evolution, the murine sequences appear to have suffered a similar
frameshift mutation in the C-terminal domain when compared to the
sequences fromman, chicken, frog and ﬁsh [9]. They contain only half
of the histidine-rich domain but possess an extension of the
polypeptide to amino acid residue 529. Nevertheless, the full-length
protein from mice reveals a subcellular distribution virtually identical
to that of human full-length FGFRL1 with the majority of the protein
found in the endoplasmic reticulum, the Golgi and the secretory
vesicles (Rieckmann and Trueb, unpublished). It remains to be
determined why the murine protein does not display the altered
subcellular distribution observed with the mutant FGFRL1 protein
from the ABS patient.
Since genital abnormalities are usually not observed in craniosy-
nostosis syndromes caused by FGFR mutations (Apert, Crouzon,
Pfeiffer, Jackson-Weiss), Reardon et al. proposed that Antley–Bixler
syndrome with genital and steroid abnormalities might be explained
by a “digenic disorder” involving one factor related to FGF signaling
and another factor related to genital development [21]. However, so
far all Antley–Bixler patients with veriﬁed FGFR2 mutations
segregated completely from those with genital abnormalities and
veriﬁed P450 oxidoreductase mutations [19]. The identiﬁcation of an
FGFRL1 mutation in combination with P450 oxidoreductase muta-
tions in a patient with abnormal steroid proﬁles now fuels the
hypothesis that Antley–Bixler syndrome might represent a digenic
disorder in some patients. Another patient that may support this
conclusion was described in 2004 by Hurley et al. [27]. This patient
presented with craniosynostosis, radio-ulnar synostosis and ambig-
uous genitalia and harbored both a dominant FGFR1 mutation
(I300T) and two heterozygous P450 oxidoreductase mutations. It is
conceivable that other mutations in additional components of the
FGF signaling system (syndecan, Sef, FRS2, FLRT3) may also
contribute to the pathogenesis of this syndrome. So far we have
analyzed the FGFRL1 gene from 109 controls and 55 craniosynostosis
patients including six Antley–Bixler patients but we did not ﬁnd any
additional alterations except the frame shift mutation of patient
14683.Acknowledgements
This study was supported by grants from the Swiss National
Science Foundation (3100A0-113806) and the Swiss Foundation for
Research on Muscular Diseases.
References
[1] N. Itoh, The Fgf families in humans, mice, and zebraﬁsh: their evolutional
processes and roles in development, metabolism, and disease, Biol. Pharm. Bull. 30
(2007) 1819–1825.
[2] N. Itoh, D.M. Ornitz, Evolution of the Fgf and Fgfr gene families, Trends Genet. 20
(2004) 563–569.
[3] V.P. Eswarakumar, I. Lax, J. Schlessinger, Cellular signaling by ﬁbroblast growth
factor receptors, Cytokine Growth Factor Rev. 16 (2005) 139–149.
[4] M. Mohammadi, S.K. Olsen, O.A. Ibrahimi, Structural basis for ﬁbroblast growth
factor receptor activation, Cytokine Growth Factor Rev. 16 (2005) 107–137.
[5] M. Wiedemann, B. Trueb, Characterization of a novel protein (FGFRL1) from
human cartilage related to FGF receptors, Genomics 69 (2000) 275–279.
[6] I. Kim, S.-O. Moon, K.-H. Yu, U.-H. Kim, G.Y. Koh, A novel ﬁbroblast growth factor
receptor-5 preferentially expressed in the pancreas, Biochim. Biophys. Acta 1518
(2001) 152–156.
[7] M. Sleeman, J. Fraser, M. McDonald, S. Yuan, D. White, P. Grandison, K. Kumble, J.D.
Watson, J.G. Murison, Identiﬁcation of a new ﬁbroblast growth factor receptor,
FGFR5, Gene 271 (2001) 171–182.
[8] M. Wiedemann, B. Trueb, The mouse Fgfrl1 gene coding for a novel FGF receptor-
like protein, Biochim. Biophys. Acta 1520 (2001) 247–250.
[9] B. Trueb, L. Zhuang, S. Taeschler, M. Wiedemann, Characterization of FGFRL1, a
novel FGF receptor preferentially expressed in cartilage, J. Biol. Chem. 278 (2003)
33857–33865.
[10] B. Trueb, S.C.F. Neuhauss, S. Baertschi, T. Rieckmann, C. Schild, S. Taeschler, Fish
possess multiple copies of fgfrl1, the gene for a novel FGF receptor, Biochim.
Biophys. Acta 1727 (2005) 65–74.
[11] M. Beyeler, B. Trueb, Fgfrl1, a ﬁbroblast growth factor receptor-like gene, is found
in the cephalochordate Branchiostoma ﬂoridae but not in the urochordate Ciona
intestinalis, Comp. Biochem. Physiol. B Biochem. Mol. Biol. 145 (2006) 43–49.
[12] T. Rieckmann, I. Kotevic, B. Trueb, The cell surface receptor FGFRL1 forms
constitutive dimers that promote cell adhesion, Exp. Cell Res. 314 (2008)1071–1081.
[13] B. Trueb, S. Taeschler, Expression of FGFRL1, a novel ﬁbroblast growth factor
receptor, during embryonic development, Intl. J. Mol. Med. 17 (2006) 617–620.
[14] C. Schild, B. Trueb, Aberrant expression of FGFRL1, a novel FGF receptor, in ovarian
tumors, Int. J. Mol. Med. 16 (2005) 1169–1173.
[15] C. Hall, M.V. Flores, G. Murison, K. Crosier, P. Crosier, An essential role for zebraﬁsh
Fgfrl1 during gill cartilage development, Mech. Dev. 123 (2006) 925–940.
[16] S. Baertschi, L. Zhuang, B. Trueb, Mice with a targeted disruption of the Fgfrl1 gene
die at birth due to alterations in the diaphragm, FEBS J. 274 (2007) 6241–6253.
[17] A.O. Wilkie, Bad bones, absent smell, selﬁsh testes: the pleiotropic consequences
of human FGF receptor mutations, Cytokine Growth Factor Rev. 16 (2005)
187–203.
[18] X. Coumoul, C.X. Deng, Roles of FGF receptors in mammalian development and
congenital diseases, Birth Defects Res. C Embryo Today 69 (2003) 286–304.
[19] N. Huang, A.V. Pandey, V. Agrawal, W. Reardon, P.D. Lapunzina, D. Mowat, E.W.
Jabs, G. Van Vliet, J. Sack, C.E. Flück, W.L. Miller, Diversity and function of
mutations in P450 oxidoreductase in patients with Antley–Bixler syndrome and
disordered steroidogenesis, Am. J. Hum. Genet. 76 (2005) 729–749.
[20] P. Jaakkola, T. Vihinen, A. Maatta, M. Jalkanen, Activation of an enhancer on the
syndecan-1 gene is restricted to ﬁbroblast growth factor family members in
mesenchymal cells, Mol. Cell Biol. 17 (1997) 3210–3219.
[21] W. Reardon, A. Smith, J.W. Honour, P. Hindmarsh, D. Das, G. Rumsby, I. Nelson, S.
Malcolm, L. Ades, D. Sillence, D. Kumar, C. DeLozier-Blanchet, S. McKee, T. Kelly,
W.L. McKeehan, M. Baraitser, R.M. Winter, Evidence for digenic inheritance in
some cases of Antley–Bixler syndrome? J. Med. Genet. 37 (2000) 26–32.
[22] C.E. Flück, T. Tajima, A.V. Pandey, W. Arlt, K. Okuhara, C.F. Verge, E.W. Jabs, B.B.
Mendonca, K. Fujieda, W.L. Miller, Mutant P450 oxidoreductase causes disordered
steroidogenesis with and without Antley–Bixler syndrome, Nat. Genet. 36 (2004)
228–230.
[23] W. Arlt, E.A. Walker, N. Draper, H.E. Ivison, J.P. Ride, F. Hammer, S.M. Chalder, M.
Borucka-Mankiewicz, B.P. Hauffa, E.M. Malunowicz, P.M. Stewart, C.H. Shackleton,
Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and
human androgen synthesis: analytical study, Lancet 363 (2004) 2128–2135.
[24] H. Ueno, M. Gunn, K. Dell, A. Tseng Jr., L. Williams, A truncated form of ﬁbroblast
growth factor receptor 1 inhibits signal transduction by multiple types of
ﬁbroblast growth factor receptor, J. Biol. Chem. 267 (1992) 1470–1476.
[25] J.S. Bonifacino, L.M. Traub, Signals for sorting of transmembrane proteins to
endosomes and lysosomes, Annu. Rev. Biochem. 72 (2003) 395–447.
[26] Z. Ahmed, A.C. Schüller, K. Suhling, C. Tregidgo, J.E. Ladbury, Extracellular point
mutations in FGFR2 elicit unexpected changes in intracellular signalling, Biochem.
J. 413 (2008) 37–49.
[27] M.E. Hurley, M.J. White, A.J. Green, J. Kelleher, Antley–Bixler syndrome with
radioulnar synostosis, Pediatr. Radiol. 34 (2004) 148–151.
